Modulation of 5-fluorouracil with methotrexate and low-dose N- (phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma

Annals of Oncology

Volumn 8, Issue 9, 1997, Pages 917-918

  Harstrick, A ^a   Kohne C H ^b   Hiddemann, W ^c   Preusser, P ^d   Strumberg, D ^a   Berns, T ^d   Seeber, S ^a   Wilke, H ^a   Schmoll, H J ^e  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

5 Fluorouracil; Biochemical modulation; Methotrexate; Pancreatic cancer; Phosphonacetyl L aspartate

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE; SPARFOSIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; FEMALE; FLUOROURACIL; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHONOACETIC ACID;

EID: 0030780051     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008298102758     Document Type: Article

References (10)

1. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995; 6: 19-28.
2. Palmer KR, Kerr M, Knowles G et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-5.
3. Cadman ED, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 1979; 205: 1135-7.
4. Casper ES, Vale K, Williams LJ et al. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacety)-L-aspartic acid. Cancer Res 1983; 43: 2324-9.
5. O'Dwyer PJ. The role of low-dose PALA in biochemical modulation. Pharmcol Ther 1990; 48: 371-80.
6. O'Dwyer PJ, Paul AR, Walczak J et al. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 1990; 8: 1497-503.
7. Rougier P, de Forni M, Adenis A et al. Phase II study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1994; 13; 200.
8. Buris III HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-13.
9. Crown J, Casper ES, Botet J et al. Lack of efficacy of high dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9: 1682-6.
10. Marsh JC, Bertino JR, Katz KH et al. The influence of drug intervall on the effect of methotrexate and fluororuacil in the treatment of advanced colorectal cancer. J Clin Oncol 1991; 9: 371-80.